A61K 38/03
Peptides having up to 20 amino acids in an undefined or only
Official title: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
A61K38/03 (Peptides having up to 20 amino acids in an undefined or only) appears on 179 US grants and 317 published applications in this corpus.
Search patents in A61K- Granted patents
- 179
- Published applications
- 317
- Assignees
- 210
- Inventors
- 566
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 2 |
| 2003 | 2 | 1 |
| 2004 | 1 | 4 |
| 2005 | 2 | 4 |
| 2006 | 4 | 4 |
| 2007 | 1 | 4 |
| 2008 | 0 | 5 |
| 2009 | 2 | 8 |
| 2010 | 3 | 8 |
| 2011 | 3 | 9 |
| 2012 | 3 | 9 |
| 2013 | 7 | 14 |
| 2014 | 10 | 19 |
| 2015 | 11 | 11 |
| 2016 | 11 | 12 |
| 2017 | 7 | 26 |
| 2018 | 14 | 27 |
| 2019 | 18 | 29 |
| 2020 | 23 | 29 |
| 2021 | 17 | 17 |
| 2022 | 8 | 18 |
| 2023 | 7 | 16 |
| 2024 | 7 | 13 |
| 2025 | 8 | 17 |
| 2026 | 2 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Formulation for oral delivery of proteins, peptides and small molecules with poor permeability12 May 2026US 12,622,968 B2Pfizer Ireland Pharmaceuticals
- Peptide-containing composition for use for treating neoplastic lesions14 Apr 2026US 12,599,646 B2Cytovation Asa
- Formulation for oral delivery of proteins, peptides and small molecules with poor permeability4 Nov 2025US 12,458,699 B2R.P. Scherer Technologies, LLC
- Plasmodium sporozoite NPDP peptides as vaccine and target novel malaria vaccines and antibodies binding to12 Aug 2025US 12,383,609 B2Institute for Research in Biomedicine
- Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response29 Jul 2025US 12,370,255 B2Barinthus Biotherapeutics North America, Inc.
- Peptide compounds to regulate the complement system24 Sep 2026US 2026/0285907 A1Realta Holdings, LLC
- Multispecific molecules for modulating t-cell activity, and uses thereof27 Aug 2026US 2026/0248911 A1Regeneron Pharmaceuticals, Inc.
- Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response27 Aug 2026US 2026/0248912 A1Barinthus Biotherapeutics North America, Inc.
- Endotoxin neutralising agent20 Aug 2026US 2026/0242413 A1Amferia AB
- Hair growth and anti-hair greying composition13 Aug 2026US 2026/0232751 A1
Most cited
By later US patents
- Submicron emulsions for delivery of peptides153US 5,514,670 APharmos Corporation · 1996
- Transcutaneous delivery of therapeutic agents49US 8,728,491 B2Alba Therapeutics Corporation · 2014
- Methods for preventing or treating ischemia-reperfusion injury of the kidney43US 7,718,620 B2Cornell Research Foundation, Inc. · 2010
- Methods for preventing mitochondrial permeability transition34US 7,576,061 B2Cornell Research Foundation, Inc. · 2009
- Peptidomimetic macrocycles34US 8,927,500 B2Aileron Therapeutics, Inc. · 2015